Drug profile · INN
selinexor
XPOVIO
selinexor (XPOVIO) is a exportin-1 inhibitor. Associated with Shanghai Antengene Corporation Limited. Route of administration: oral. Current US regulatory status: approved.
Drug details — selinexor
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 20
- Programs
- 65
- Data quality
- 0.89
Quick answer
selinexor (XPOVIO) is a exportin-1 inhibitor. Associated with Shanghai Antengene Corporation Limited. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Exportin-1 inhibitor
Primary target: Exportin-1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 12371420
Polymorphs of Selinexor
granted -
US 12291508
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 12076418
Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
granted -
US 11807629
Polymorphs of Selinexor
granted -
US 11787771
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 11753401
Polymorphs of Selinexor
granted -
US 11746102
Polymorphs of selinexor
granted -
US 11623011
Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
granted -
US 11078190
Polymorphs of selinexor
granted -
US 11052157
Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
granted -
US 11034660
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 10647785
High concentration chitosan-nucleic acid polyplex compositions
granted -
US 10544108
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 10519139
Polymorphs of Selinexor
granted -
US 10328159
Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
granted -
US 9850323
High concentration chitosan-nucleic acid polyplex compositions
granted -
US 9714226
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 9623112
Dually derivatized chitosan nanoparticles and methods of making and using the same
granted -
US 9079865
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 8999996
Hydrazide containing nuclear transport modulators and uses thereof
granted
Frequently asked questions
What is selinexor?
selinexor (XPOVIO) is a exportin-1 inhibitor. Associated with Shanghai Antengene Corporation Limited. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for selinexor?
XPOVIO is a marketed brand name for selinexor. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of selinexor?
selinexor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.